ea0037gp.22.05 | Pituitary–Therapy of Cushing's disease | ECE2015
Ting Lillian
, Tripathi Anadya Prakash
, Darstein Christelle
, White Tracy
, Sauter Nicholas
Introduction: In vitro assessments of osilodrostat (LCI699), a potent oral inhibitor of 11β-hydroxylase suggested potential drugdrug interactions (DDIs) with cytochrome P450 (CYP) enzyme metabolism. This clinical study evaluated the effect of osilodrostat on the pharmacokinetics (PK) of CYP1A2, CYP2C19, CYP2D6, and CYP3A4 probe substrates, caffeine, omeprazole, dextromethorphan, and midazolam, respectively.Methods: A single-centre, op...